Literature DB >> 10193361

Treatment of central sleep apnoea in congestive heart failure with nasal ventilation.

G N Willson1, I Wilcox, A J Piper, W E Flynn, R R Grunstein, C E Sullivan.   

Abstract

Entities:  

Mesh：

Year:  1998        PMID： 10193361      PMCID： PMC1765914          DOI： 10.1136/thx.53.2008.s41

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  23 in total

1.  Occult sleep-disordered breathing in stable congestive heart failure.

Authors:  S Javaheri; T J Parker; L Wexler; S E Michaels; E Stanberry; H Nishyama; G A Roselle
Journal:  Ann Intern Med       Date:  1995-04-01       Impact factor: 25.391

2.  Pathogenesis of Cheyne-Stokes respiration in patients with congestive heart failure. Relationship to arterial PCO2.

Authors:  P Hanly; N Zuberi; R Gray
Journal:  Chest       Date:  1993-10       Impact factor: 9.410

3.  Spontaneous variability of ventricular function in patients with chronic heart failure. The Western Enoximone Study Group and the REFLECT Investigators.

Authors:  K A Narahara
Journal:  Am J Med       Date:  1993-11       Impact factor: 4.965

4.  Cardiac failure and benzodiazepines.

Authors:  C Guilleminault; A Clerk; M Labanowski; J Simmons; R Stoohs
Journal:  Sleep       Date:  1993-09       Impact factor: 5.849

5.  Treatment of respiratory failure during sleep in patients with neuromuscular disease. Positive-pressure ventilation through a nose mask.

Authors:  E R Ellis; P T Bye; J W Bruderer; C E Sullivan
Journal:  Am Rev Respir Dis       Date:  1987-01

6.  Central sleep apnea is associated with increased ventilatory response to carbon dioxide and hypersecretion of growth hormone in patients with acromegaly.

Authors:  R R Grunstein; K Y Ho; M Berthon-Jones; D Stewart; C E Sullivan
Journal:  Am J Respir Crit Care Med       Date:  1994-08       Impact factor: 21.405

7.  Role of hyperventilation in the pathogenesis of central sleep apneas in patients with congestive heart failure.

Authors:  M Naughton; D Benard; A Tam; R Rutherford; T D Bradley
Journal:  Am Rev Respir Dis       Date:  1993-08

8.  Treatment of congestive heart failure and Cheyne-Stokes respiration during sleep by continuous positive airway pressure.

Authors:  M T Naughton; P P Liu; D C Bernard; R S Goldstein; T D Bradley
Journal:  Am J Respir Crit Care Med       Date:  1995-01       Impact factor: 21.405

9.  Effect of continuous positive airway pressure on central sleep apnea and nocturnal PCO2 in heart failure.

Authors:  M T Naughton; D C Benard; R Rutherford; T D Bradley
Journal:  Am J Respir Crit Care Med       Date:  1994-12       Impact factor: 21.405

10.  Cheyne-Stokes breathing during sleep in patients with left ventricular heart failure.

Authors:  L J Findley; C W Zwillich; S Ancoli-Israel; D Kripke; G Tisi; K M Moser
Journal:  South Med J       Date:  1985-01       Impact factor: 0.954
View more
  4 in total

Review 1.  The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses.

Authors:  R Nisha Aurora; Susmita Chowdhuri; Kannan Ramar; Sabin R Bista; Kenneth R Casey; Carin I Lamm; David A Kristo; Jorge M Mallea; James A Rowley; Rochelle S Zak; Sharon L Tracy
Journal:  Sleep       Date:  2012-01-01       Impact factor: 5.849

Review 2.  Central sleep apnoea syndrome in patients with chronic heart disease: a critical review of the current literature.

Authors:  T Köhnlein; T Welte; L B Tan; M W Elliott
Journal:  Thorax       Date:  2002-06       Impact factor: 9.139

Review 3.  Cheyne-stokes respiration in patients with heart failure.

Authors:  Laila AlDabal; Ahmed S BaHammam
Journal:  Lung       Date:  2009-12-03       Impact factor: 2.584

4.  Postprandial glucose and HbA1c are associated with severity of obstructive sleep apnoea in non-diabetic obese subjects.

Authors:  A Cignarelli; A Ciavarella; M Barbaro; S Kounaki; A Di Trani; V A Falcone; V N Quaranta; A Natalicchio; L Laviola; O Resta; F Giorgino; S Perrini
Journal:  J Endocrinol Invest       Date:  2021-06-26       Impact factor: 4.256
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.